ARCA biopharma ABIO and Duke University's Duke Clinical Research Institute (DCRI), the
world's largest academic clinical research organization (ARO), today
announced a new agreement under which ARCA and the DCRI will work
together to execute GENETIC-AF, a planned Phase 2B/3
genetically-targeted, comparative effectiveness clinical trial
evaluating Gencaro™ (bucindolol hydrochloride) as a potential treatment
for the prevention of atrial fibrillation (AF) in patients with heart
failure. Patient enrollment in GENETIC-AF is expected to begin in the
first quarter of 2014.
ARCA has identified common genetic variations that it believes predict
individual patient response to Gencaro, giving it the potential
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in